Cite
HARVARD Citation
Edwards, C. et al. (2014). SAT0389 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-Term (52-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Results from the Palace 4 Phase 3, Randomized, Controlled Trial. Annals of the rheumatic diseases. p. 735. [Online].